DTILPrecision Biosciences Inc
DTIL
Precision Biosciences Inc3,726
Mkt Cap
$195.58MVolume
54,539.0052W High
$8.8252W Low
$3.53PE Ratio
-2.04DTIL Fundamentals
Price
$7.58Prev Close
$7.23Open
$7.3550D MA
$7.00Beta
0.77Avg. Volume
222,523.12EPS (Annual)
-$3.63P/B
2.57Rev/Employee
$503,882.35$33.42
Precision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the presentation of new and late-breaking clinical data from the ELIMINATE-B study...
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will host an investor webcast to discuss new biopsy and clinical data from...
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Precision BioSciences (NASDAQ:DTIL) Releases Quarterly Earnings Results, Misses Estimates By $0.09 EPS
Precision BioSciences (NASDAQ:DTIL - Get Free Report) issued its earnings results on Tuesday. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts' consensus...
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
Precision BioSciences (DTIL) delivered earnings and revenue surprises of -25.93% and +40.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today reported financial results for the first quarter ended March 31, 2026, and provided a...
Nuvation Bio Inc. (NUVB) Lags Q1 Earnings Estimates
Nuvation Bio (NUVB) delivered earnings and revenue surprises of -91.30% and +0.36%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Precision BioSciences (DTIL) Projected to Post Earnings on Tuesday
Precision BioSciences (NASDAQ:DTIL) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-5-precision-biosciences-inc-stock...
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need...
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS platform to develop in vivo gene editing therapies for high unmet need diseases, today announced the activation of the first clinical trial site and the opening of patient...
<
1
2
...
>
Compact View
Not available
Not available
Advertisement|Remove ads.
Latest DTIL News
ViewPrecision BioSciences Announces New and Late-Breaking PBGENE-HBV Clinical Data from the ELIMINATE-B Study at European Association for the Study of the Liver Congress 2026
Precision BioSciences to Host Investor Webcast to Discuss Late-Breaking PBGENE-HBV Data from ELIMINATE-B Trial Presented at European Association for the Study of the Liver Congress 2026
Precision BioSciences Presents New Preclinical Data Supporting the Advancement of PBGENE-DMD into Clinic at the American Society of Gene & Cell Therapy 2026 Annual Meeting
Advertisement|Remove ads.